September 26, 2023

Good morning everybody, from STAT reporter Andrew Joseph right here filling in for Ed. Or, if I’m being trustworthy, good afternoon. No, this isn’t some snap within the space-time continuum. Reasonably, I’m writing to you from STAT’s new outpost in London. That’s proper, STAT’s gone world. I’ve moved over right here to increase our protection of European biopharma and well being information, so do get in contact if in case you have concepts for what I needs to be looking at. Now, sufficient delay. On to the pharma headlines you search. …

Eli Lilly’s drug Mounjaro for kind 2 diabetes helped people who find themselves additionally obese or overweight lose as much as 15.7% of their physique weight, in a brand new research that might pave the way in which for Lilly to advertise the drug as a weight-loss therapy, the Wall Street Journal writes. Lilly stated that with the brand new information, it’ll full within the coming weeks an software to the U.S. Meals and Drug Administration to market Mounjaro as an anti-obesity therapy, which might allow an FDA determination by the top of the yr. Lilly’s Mounjaro was permitted final yr as a diabetes therapy, although some folks already use it off-label for weight reduction. Additionally Thursday, Lilly raised its annual income and revenue forecasts after topping first-quarter gross sales estimates, because of demand for Mounjaro, Reuters tells us.

Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!